Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ PRAME Biosimilar Recombinant Monoclonal Antibody

Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term Eureka patent anti-PRAME.
This gene encodes an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, this gene is also expressed in acute leukemias. Five alternatively spliced transcript variants encoding the same protein have been observed for this gene.
Specifications
Specifications
| Antigen | PRAME (Biosimilar) |
| Applications | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Classification | Recombinant Monoclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 |
| Gene | PRAME |
| Gene Accession No. | P78395 |
| Gene Alias | 4930534P07Rik; cancer/testis antigen 130; CT130; MAPE; melanoma antigen preferentially expressed in tumors; OIP4; OIP-4; Opa-interacting protein 4; Opa-interacting protein OIP4; PRAME; preferentially expressed antigen in melanoma; preferentially expressed antigen of melanoma |
| Gene Symbols | PRAME |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?